RTP Mobile Logo
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Hepatocellular Carcinoma (Video Program)
Released November 2020

Featuring a roundtable discussion with Drs Thomas A Abrams, Anthony El-Khoueiry and Robin K Kelley. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.


    • Consider patient age, performance status, liver function and other clinical and disease-specific factors in the management of advanced hepatocellular carcinoma (HCC).
    • Assess available Phase III data documenting the efficacy of atezolizumab in combination with bevacizumab as first-line therapy for patients with unresectable or metastatic HCC, and consider the current role of this novel regimen.
    • Understand the scientific rationale for and recall available clinical trial data with approved and investigational immune checkpoint inhibitors, alone and in combination with targeted agents, in the treatment of HCC.
    • Appraise available data with and consider the clinical role of agents targeting angiogenesis in therapy for patients with HCC.
    • Educate patients about the incidence and manifestation of side effects associated with existing and emerging targeted agents and immunotherapeutic approaches in the management of advanced HCC.
    • Recall available and emerging data with other agents and strategies currently under clinical investigation for HCC.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Thomas A Abrams, MD
    Senior Physician
    Dana-Farber Cancer Institute
    Assistant Professor of Medicine
    Harvard Medical School
    Director, Liver Tumor Center
    Boston, Massachusetts

    Advisory Committee: Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck; Ownership Interest: Biogen, Guardant Health.

    Anthony El-Khoueiry, MD
    Associate Professor of Clinical Medicine
    Medical Director of Clinical Investigations Support Office
    Phase I Program Director
    USC Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee: Agenus Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Roche Laboratories Inc; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Merck.

    Robin K Kelley, MD
    Associate Professor of Clinical Medicine
    Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco
    San Francisco, California

    Advisory Committee (Payments to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Merck; Consulting Agreements: Bristol-Myers Squibb Company (payment to institution), Exact Sciences, Genentech, a member of the Roche Group, Gilead Sciences Inc; Contracted Research: Adaptimmune, Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Exelixis Inc, Lilly, Merck, Novartis, Partner Therapeutics, QED Therapeutics, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group; Paid Travel: Ipsen Biopharmaceuticals Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, a member of the Roche Group, and Lilly.

    Release date: November 2020
    Expiration date: November 2021

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

First-Line Systemic Therapy for Patients with Unresectable Hepatocellular Carcinoma (HCC)

Clinical Decision-Making for Patients with Progressive Metastatic HCC

Select Publications